Introduction {#S5}
============

Obesity is a major risk factor for the development of nonalcoholic fatty liver disease (NAFLD), which represents a spectrum of clinical manifestations, progressing from hepatic steatosis, nonalcoholic steatohepatitis, to fibrosis and cirrhosis ^[@R1]^. NAFLD is characterized by excessive hepatic fat deposition by increased lipid influx ^[@R2]^, de novo lipogenesis ^[@R3]^, impaired mitochondrial β-oxidation ^[@R4]^ and/or reduced lipid export ^[@R5]^. The Obese Zucker rat (OZR) is a preclinical rodent model of NAFLD and is frequently used in obesity-related research ^[@R6],\ [@R7]^.

Dietary intake of soy protein has several nutritional and physiological benefits^[@R8]^, including anti-obesity and anti-diabetic properties ^[@R9]^. In addition, soy protein isolate (SPI) is shown to improve lipid metabolism in obese rodents ^[@R10]^, as well as to reduce lipogenic activities and hepatic triacylglycerol (TAG) accumulation ^[@R11]^. In OZR rats where NAFLD naturally occurs ^[@R7]^, SPI is shown to modify adipose morphology and metabolic profile, as well as to improve inflammatory status ^[@R12]^.

The Wnt/β-catenin signaling pathway is central to adipogenic regulation in adipose tissue/cells ^[@R13]^ and skeletal muscle ^[@R14]^. In particular, Wnt signaling inhibits the adipogenic transcription factors CCAAT/enhancer binding protein α (*C/EBPα*) and peroxisome proliferator- activated receptor (*PPAR*) γ, thereby preventing the maturation of preadipocytes. It has also been demonstrated that disruption of the Wnt pathway in myoblasts promotes trans-differentiation of these cells into adipocytes ^[@R15]^. Thus, Wnt signaling is proposed to affect/control lipid deposition through antagonism of fat tissue development. Recent evidence has established a potential link between the Wnt pathway and lipid regulation in liver tissue. In a mouse model it has been demonstrated that hepatic fat accumulation was increased by liver-specific β-catenin knockout ^[@R16]^. Later, Cain *et al* reported that a reduction in hepatic lipid content in OZR rats fed SPI was associated with lower expression of Wnt signaling intermediates, including *Dact1*, *GSK3β*, *Wnt5a* and *Wnt5b*^[@R12]^. However, it is unclear how different components of Wnt signaling, such as β-catenin, are affected by obesity or soy protein. Therefore, in the current study we investigated the interaction between SPI, β-catenin signaling, and hepatic steatosis in OZR rats. In addition, we used a rat hepatoma-based cell culture model to elucidate the specific mechanisms linking Wnt/β-catenin signaling to liver fat accumulation.

Methods {#S6}
=======

Animal Model and Diet {#S7}
---------------------

Six-week old male homozygous lean and obese Zucker rats were purchased from Charles River Laboratories and randomly assigned to diets containing either casein or SPI as protein source for 17 weeks ^[@R12]^. All procedures were approved by the Institutional Animal Care and Use Committee of Southern Illinois University, Carbondale, IL, USA.

Liver histology and Cell staining {#S8}
---------------------------------

Frozen liver samples were embedded in Tissue-Tek OCT compound (VWR) and cut to a thickness of 5 μm in a cryostat at -20°C. All sections were fixed in 70% ethanol and stained with hematoxylin and eosin (H&E) or Oil red O (ORO) solution (Newcomer Supply). Histopathological examination was conducted by a certified pathologist. Oil red O (ORO) staining was quantified using the AxioVision software. The grading scale of histopathological examination used to assess microscopic pathological findings was 0: none, 1: minimal, 2: mild, 3: moderate, 4: marked and 5: severe. Images of ORO staining were obtained using NanoZoomer Slide Scanner and NDP View software (Hamamatsu).

Biochemical analysis of liver tissue {#S9}
------------------------------------

Frozen liver samples were ground in liquid nitrogen and homogenized in 0.3mL saline (0.9% w/v NaCl). Homogenized samples were diluted 5 times with saline. Twenty microliter of the diluted samples were incubated with 20 μL 1% deoxycholate in 37 °C for 5 min and 10 μL of the sample were analyzed using the Thermo Infinity Triglycerides Liquid Stable Reagent (Thermo Fisher Scientific) and a standard reference kit (Verichem Laboratories) to determine the TAG content. Liver non-esterified fatty acid (NEFA) concentration was determined using a commercially available kit (HR-2 Series, Wako Diagnostics). The results were normalized to the amount of total protein in the sample. Extracted serum was analyzed for aspartate aminotransferase (AST) and alanine aminotransferase (ALT) using the Beckman CX4 Chemistry Analyzer.

RNA isolation and real time quantitative RT-PCR {#S10}
-----------------------------------------------

Total RNA was extracted from liver samples using TRI reagent (Sigma-Aldrich). cDNA was synthesized from the total RNA using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) in a Thermal Cycler (Applied Biosystems) at 25 °C for 10 min, 37 °C for 2 h and 85 °C for 5 s. Real time PCR was then performed using SYBR Green fast master mix (Quanta Biosciences) in a 7300 real-time thermal cycler (Applied Biosystems) at 95 °C for 10 min, followed by 35 cycles of 95 °C for 15 s and 60 °C for 1 min. Relative mRNA quantity for the ribosomal protein L7a was measured and used as the internal control. Primers used for PCR are listed in [Supplemental Table 1](#SD1){ref-type="supplementary-material"}.

Immunofluorescent staining {#S11}
--------------------------

Frozen liver samples were embedded in Tissue-Tek OCT compound (VWR, Radnor, PA) and cut to a thickness of 5 μm in a cryostat at -20 °C. The sections were fixed in 70% ethanol, permeablized with 0.1% Triton X-100, blocked with Image-iT FX signal enhancer (Invitrogen) for 30 min, incubated with primary antibody (β-catenin, cat \# 9587S, Cell Signaling) for 2 h at 37 °C, and followed by an incubation of a goat anti-rabbit antibody (Alexa Fluor 647 1:200 dilution, Invitrogen) for 45 min in a dark chamber. The samples were counterstained with Hoechst 33342 (Invitrogen) for 15 min and then washed with PBS. Coverslip was mounted on the sections using Prolong Gold antifade reagent (Invitrogen). Pictures were taken using the Axiovert 200M equipment (Zeiss).

Cell culture and short interfering RNA (siRNA) assay {#S12}
----------------------------------------------------

The rat hepatoma cell line H4IIEC3 was obtained from American Type Culture Collection and was cultured in Minimum Essential Medium (MEM) supplemented with 10% (v/v) fetal bovine serum (Sigma-Aldrich) and 100 IU/mL Penicillin, and 100 μg/mL Streptomycin (Mediatech). Cells were maintained at 37 °C in 95% humidity and 5% CO~2~. For transfection, H4IIEC3 cells were seeded onto 6-well plates and incubated overnight in MEM. At the time of transfection, 30 nmol/L of siRNA against scrambled sequence (non-specific siRNA, N/S si, QIAGEN) or 30 nmol/L of siRNA against rat β-catenin (β-catenin si, Integrated DNA Technologies) was prepared in 200 μL serum-free media (SFM). The siRNA solution was incubated with 5 μL DharmaFect\#4 (in 200 μL SFM, Dharmacon) at room temperature for 20 min to allow the formation of transfection complex. Each well of the 6-well plates was replenished with 1.6 mL antibiotic-free MEM before the transfection complex was added (400 μL/well for 6-well). Two days after transfection, cells were treated with MEM supplemented with 450 μmol/L of NEFA (containing 150 μmol/L of bovine serum albumin, BSA, Sigma-Aldrich) or 150 μmol/L of BSA alone for 24 h. Total RNA and protein was isolated and analyzed by quantitative real-time RT-PCR and western blot, respectively.

Protein extraction and western blot analysis {#S13}
--------------------------------------------

Liver tissue or cells were lysed with 1X Laemmli Buffer \[62.5 mmol/L Tris--HCl, pH 6.8, 2% SDS, 10% Glycerol v/v, 0.01% Bromophenol blue, 5% 2-mercaptoethanol, 1x protease inhibitors (Roche) and 1x phosphatase inhibitors (Sigma-Aldrich)\]. Lowry assay was performed to determine protein concentration. Samples containing 30 μg of protein were resolved on a 10% SDS-PAGE gel by electrophoresis and transferred to a PVDF membrane (0.2 μm, Bio-Rad) using wet transfer protocol. The membrane was then blocked in 10% milk in TBS/T (30 mmol/L Tris base pH 7.6, 200 mmol/L NaCl and 0.1% Tween 20) for 1 h at room temperature. The membranes were incubated with primary antibodies in 10% non-fat dry milk at a 1:2000 dilution at room temperature for 3 h. SuperSignal West Dura Extended Duration Substrate kit (Thermo Scientific) was used to detect the signal and the images were captured and analyzed by a Chemi Doc XLR system (Bio-Rad). Actin and fast green stained non-specific bands were used as a loading control to normalize the protein data.

Statistical analysis {#S14}
--------------------

Results are expressed as interaction means (diet × genotype) ± standard error of mean (SEM) in figures. Post hoc comparison among groups was tested using the Fisher\'s least significant difference (LSD, SAS v. 9.1.2, SAS Institute) when the P value of interaction of main effects (diet × genotype) was less than 0.15. Individual bars with different letters differ (P\<0.05). Correlation between hepatocellular vacuolation and AST or ALT was determined by Spearman\'s rank correlation coefficient analysis (Spearman\'s rho). Student t-test was conducted to make the comparison in cell culture study.

Results {#S15}
=======

Liver histology and functions {#S16}
-----------------------------

At the end of the 17 weeks, no or minimal to mild centrilobular hepatocellular vacuolation was observed in lean rats (**[Figure 1A](#F1){ref-type="fig"}**). In obese rats, moderate to severe (soy) and marked to severe (casein) micro- and/or macro-hepatocellular vacuolation was observed. Overall, obese rats had a significant higher vacuolation when compared to lean rats (**[Figure 1B](#F1){ref-type="fig"}**, P\<0.05; [Supplemental Table 2](#SD1){ref-type="supplementary-material"}, genotype effect, P\<0.0001). Particularly in the obese rats, the average grading score decreased from 4.86 (5 being the most severe) in control group to 3.75 in soy group (P=0.018), showing a significant decrease in severity of hepatocellular vacuolation. This suggested that SPI-fed rodents had improved pathological conditions in liver ([Supplemental Table 2](#SD1){ref-type="supplementary-material"}, diet effect, P=0.035**)**.

Aberrant AST and ALT levels are indicators of liver disease and hepatocyte damage ^[@R17]^. Data from the present study AST and ALT were significantly increased in the obese rats when compared to the lean rats (P\<0.05, **[Figure 1C](#F1){ref-type="fig"},** [Supplemental Table 2](#SD1){ref-type="supplementary-material"}, genotype effect, P\<0.0001). There is also a significant reduction of AST in soy-fed obese rats comparing to the control (P\<0.05; [Supplemental Table 2](#SD1){ref-type="supplementary-material"}, genotype\*diet interaction, P=0.087). Both AST and ALT levels are positively correlated with hepatocellular vacuolation (P\<0.001, **[Figure 1D](#F1){ref-type="fig"}.** Spearman\'s rho=0.77 and 0.76 for AST and ALT respectively). ALT was not significantly affected by the dietary treatment. This indicated that the improvement of liver condition by dietary soy may be closely associated with the reduced AST level.

Hepatic fat assessment {#S17}
----------------------

Quantification of ORO staining represents the amount of neutral lipid (**[Figure 2A and 2B](#F2){ref-type="fig"}**). Obese rats showed 3.3 fold more fat in liver compared to the lean rats (**[Figure 2B](#F2){ref-type="fig"},** P\<0.05; [Supplemental Table 2](#SD1){ref-type="supplementary-material"}, genotype effect, P=0.0179). Furthermore, the soy-based diet significantly reduced hepatic fat in the obese rats compared to the obese rats fed the casein diet (**[Figure 2B](#F2){ref-type="fig"}**, P\<0.05; diet effect, P=0.011).

Liver samples were further examined for TAG and NEFA content. TAG level was 4 fold higher in obese rats fed control diet (**[Figure 2C](#F2){ref-type="fig"},** P\<0.05; [Supplemental Table 2](#SD1){ref-type="supplementary-material"}, genotype effect, P\<0.0001). Similarly, NEFA content was \~40% higher in the control group (**[Figure 2C](#F2){ref-type="fig"},** P\<0.05; genotype effect, P=0.0053). Overall, obese rats showed greater lipid accumulation than lean rats. TAG and NEFA concentrations of the lean rats were not affected by dietary treatment. However, dietary soy significantly reduced TAG level in the obese rats when compared to the obese rats in the control (**[Figure 2C](#F2){ref-type="fig"}**, P\<0.05; diet effect, P=0.098).

Expression of lipid metabolism-related genes {#S18}
--------------------------------------------

It was demonstrated that SPI attenuated metabolic syndrome through the regulation of *Pparα*, *Srebp1-c* and *Lxrα* expression in liver ^[@R18]^. Our analysis showed that *Srebp1-c* mRNA increased 2.76 fold in the obese rats when compared to the lean rats fed the casein diet (**[Table](#T1){ref-type="table"},** P\<0.05). This was downregulated by dietary soy (P\<0.05). *Pparα* expression was increased in obese rats (P\<0.05, [Supplemental Table 2](#SD1){ref-type="supplementary-material"}, genotype effect, P=0.0043) but was not affected by dietary treatment. On the other hand, *Lxrα* expression was not significantly affected by genotype or diet. In addition, a marker of hepatic fat content, *Adrp*^[@R19]^ increased 4 folds in the obese rats compared to the lean groups but was reduced significantly by SPI (P\<0.05, **[Table](#T1){ref-type="table"}**). These findings are consistent with the ORO staining and TAG data showing a significant genotype and diet effect on liver fat accumulation. These results also indicate that additional factors other than *Pparα*, *Srebp1-c*, and *Lxrα* may be involved in the regulation of hepatic steatosis.

Expression of Wnt genes in liver tissues {#S19}
----------------------------------------

mRNA abundance of selected Wnt ligands and antagonists ^[@R20]^ were analyzed to evaluate the involvement of the signaling pathway in fat accumulation in liver. Overall, Wnt signaling genes tested showed limited and selective responses to genotype and dietary treatments. In particular, *Wnt4* and *Wnt9a* showed a significant increase in the obese rats compared to the lean rats and the soy diet reduced the levels in the obese rats to that comparable to the obese rats in the control group (**[Table](#T1){ref-type="table"}**, P\<0.05). *Wnt2* showed modest decrease in the obese rats compared to the lean rats (genotype effect, P=0.0023) but did not show significant effect from diet. Therefore, we further analyzed transcript abundance of selected Wnt antagonists including secreted frizzled-related protein *(Sfrp) 1, 4*, *5* and Dickkopf-1 (*Dkk1*). In general, the gene expression of the antagonists was not affected greatly by genotype but in the obese rats, SPI lowered the expression of *Sfrp1, 4, 5,* and *DKK1* when compared to casein diet (**[Table](#T1){ref-type="table"}**). Repression of these antagonists potentially contributes to the effect of soy diet on β-catenin observed in this study.

β-catenin protein level in the liver {#S20}
------------------------------------

As above-mentioned, analysis of upstream Wnt signals and their antagonists gave complicated and limited information regarding overall Wnt signaling. We therefore examined expression of the key intracellular mediator of the Wnt signaling pathway, β-catenin (**[Figure 3A](#F3){ref-type="fig"}**). Results showed that liver from the obese rats had a 7-fold reduction of total β-catenin protein compared to that of lean rats (P\<0.05, **[Figure 3B](#F3){ref-type="fig"}**). Importantly, dietary soy protein restored the β-catenin protein level in liver of obese rats compared to casein (P\<0.05). Degrading form of β-catenin (p-β-catenin; **[Figure 3C](#F3){ref-type="fig"}**) was not affected by either genotype or diet, indicating that the change of β-catenin protein observed was likely due to the regulation of β-catenin expression rather than degradation.

NEFA treatment and β-catenin knockdown in H4IIEC3 cell line {#S21}
-----------------------------------------------------------

siRNA against β-catenin was used to examine the effects from the reduction of β-catenin in H4IIEC3 rat hepatoma cells. In addition to the reduction of β-catenin by siRNA, NEFA treatment further decreased β-catenin content in both N/S and β-catenin siRNA groups (P\<0.05, **[Figure 4A](#F4){ref-type="fig"}**). Reduced β-catenin alone induced cellular fat accumulation (P\<0.05, β-catenin si compared to N/S si, **[Figure 4B, 4C](#F4){ref-type="fig"}**), although NEFA treatment further induced more pronounced total fat accumulation compared to BSA control.

Discussion {#S22}
==========

The present study demonstrated that SPI reduced hepatic fat accumulation and markers of liver dysfunction in the OZR rats. Hepatic Wnt/β-catenin signaling was down-regulated in the obese animals, and soy protein in the diet markedly corrected this effect as evident from the increased protein level of β-catenin. This study illustrated, for the first time, that dietary soy alleviates hepatic fat accumulation in the obese rats, potentially through the repression of Wnt antagonists and restoration of intracellular β-catenin signaling.

Wnt/β-catenin signaling pathway is reportedly involved in obesity in bone ^[@R21]^, colon ^[@R22]^, adipose tissue ^[@R23]^, and the placenta ^[@R24]^. In our study, obese animals exhibited decreased β-catenin signaling in the liver and an overall increase in hepatic fat. Specifically, loss of the central component of the Wnt signaling, β-catenin, is reported to affect multiple aspects of liver development and functions, including increased risk of hepatocarcinogenesis ^[@R25]^, defective cholesterol metabolism and increased susceptibility to steatohepatitis ^[@R16]^. The current study is novel to report the repression of β-catenin during hepatic fat accumulation in obese animals.

Wnt signaling pathway was shown to inhibit the development of fat cells thereby blocking adipogenesis in cell culture ^[@R15]^. For instance, expression of *Wnt10b* decreases fat deposits and reduces obesogenic activities ^[@R26]^. Further, conditional deletion of β-catenin in mesenchymal cells during embryogenesis results in a progressive switch from muscle cells to adipocytes ^[@R27]^. In the present study in liver, the restored/increased intracellular β-catenin level appeared to be a major effect from SPI in the obese rats. We observed less response from the Wnt signaling genes and more inverse correlation between β-catenin level and Wnt antagonists. Expressions of Wnt antagonists, including *Dkk1*^[@R28]^, *Sfrp 1*^[@R29]^ and 5 ^[@R30]^ were shown to induce lipid accumulation and increase total adiposity. Hence, the downregulation of Wnt antagonists in the liver of the obese rats by SPI is potentially associated with the restoration of β-catenin level and therefore the reduction of hepatic fat accumulation. Obese individuals with NAFLD showed inhibited regeneration capacity through reduced proliferation of hepatocytes ^[@R31]^. Thus, it is likely that dietary soy reverses the repression of β-catenin and promotes cell proliferation, leading to attenuated fat accumulation. Future studies are needed to further investigate the mechanisms involving the Wnt antagonists in β-catenin during hepatic fat accumulation.

H4IIEC3 rat hepatoma cells represent an excellent model for studying cellular mechanisms of hepatic fat accumulation in obesity, as NEFA treatment in these cells similarly results in marked intracellular lipid accumulation. In the present study, NEFA treatment reduced β-catenin level, confirming the observation made in the obese rat model. Direct knockdown of β-catenin in hepatoma cells also increased lipid accumulation. These results suggest that lipid accumulation is associated with reduced intracellular β-catenin in both liver tissue and hepatoma cells. There have been reports indicating interactions between β-catenin and other signaling pathways in different hepatic cell types during cell-to-cell communications ^[@R32]-[@R34]^. Therefore further investigations of β-catenin signaling and interactions with other signaling pathways during hepatic fat accumulation may illustrate the mechanisms of the protective effects from dietary soy.

Soy protein conveys a variety of health-beneficial effects, including alleviation of some symptoms related to obesity ^[@R12],\ [@R35]^. It was proposed that unique amino acid composition and bioactive components such as saponins and isoflavonoids are potentially responsible for these effects ^[@R36]-[@R39]^. Early study reported that genistein, one of the major soy isoflavones, represses adipogenic differentiation via activating Wnt/β-catenin signaling pathway ^[@R40]^. This suggested that the upregulation of Wnt/β-catenin signaling pathway reported in the present study may be attributed to these components in SPI. Further experiments are needed to identify the functional component(s) that has been working through Wnt signaling to regulate the lipid metabolism. The restoration of hepatic β-catenin level by SPI in the obese rats contributes to the protection against hepatic fat accumulation and could be developed into a potential strategy for the attenuation of hepatic steatosis and NAFLD.

Our results demonstrated that SPI in obese rats significantly reduced hepatic steatosis. Furthermore, reduction of AST by SPI in the obese rats is correlated with the reduction of liver hepatocellular vacuolation. Future experiments are needed to examine the potential effects on these parameters from the necrosis/degeneration of cells in the heart, kidney and muscle.

In conclusion, the establishment of connections between dietary soy, hepatic fat accumulation, and β-catenin signaling in liver is of major significance, in that it provides a potential mechanism of dietary effect on liver patho-physiology. We propose for the first time that dietary soy attenuates hepatic fat accumulation in a β-catenin-dependent manner, which also supports the utilization of soy as a potentially effective dietary therapy. The clinical significance and practical applications for using soy to reduce fatty liver remain to be further elucidated.
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NAFLD

:   nonalcoholic fatty liver disease

NEFA

:   non-esterified fatty acid

OZR

:   Obese Zucker rats

SPI

:   Soy protein isolate

TAG

:   Triacylglycerol

###### 'What is already known about this subject'

-   Soy protein isolate (SPI) was shown to have anti-obesity and hepato-protective effects.

-   The Wnt/β-catenin pathway is an important regulator of liver homeostasis.

###### 'What this study adds'

-   Soy protein intake significantly reduced fat accumulation in the obese Zucker rats;

-   Wnt signaling in liver is suppressed in the obese rats and is upregulated by soy protein diet;

-   Silencing of β-catenin further confirmed the involvement of Wnt signaling in controlling fat accumulation in liver.

![Histological and physiological assays in the liver of lean and obese rats\
**A.** Representative images of H&E staining in casein group (left panels) and soy group (right panels) and in lean (top panels) and obese (bottom panels) animals. No or minimal hepatocellular vacuolation was noted in lean rats (top panels); Moderate vacuolation in an obese rat with soy protein (lower right panel); Severe vacuolation in an obese rat fed with casein (lower left panel). Objective, 20x.\
**B**. Scattered plot of hepatocellular vacuolation counting. Each symbol represents one individual sample. Horizontal lines represent the mean values. \*P\<0.05, n=6\~7 individual animals per group.\
**C.** AST and ALT levels were measured in the liver of lean and obese rats. Data are presented as the mean ± SEM, n= 6. Individual bars with different letters differ (P\<0.05).\
**D.** Correlation of AST and ALT with hepatocellular vacuolation. Each symbol represents one individual sample. **×**: lean rats fed casein; □: lean rats fed soy; △: obese rats fed casein; ○: obese rats fed soy. Regression line was calculated after the analysis.](nihms-444115-f0001){#F1}

![Analysis of hepatic fat\
**A.** Representative images of Oil Red O staining. Scale bar: 500 μm.\
**B.** Quantification of Oil Red O staining is expressed as percentage of total surface area in the unit of cm^2^ using computer-assisted image quantification. The open bars represent values of the rats on casein diet while the solid bars on soy diet. Values are presented as the mean ± SEM, *n* = 10. Individual bars with different letters differ (P\<0.05). .\
**C.** TAG (top) and NEFA (bottom) levels were measured in the liver. Raw value was normalized to relative tissue protein amount. Data are presented as the mean ± SEM, n= 6. Individual bars with different letters differ (P\<0.05).](nihms-444115-f0002){#F2}

![Protein abundance of β-catenin in liver\
**A.** Immunofluorescent staining of β-catenin. Protein content of β-catenin in liver was analyzed by immunofluorescent staining using an antibody against β-catenin protein and an Alexa Fluor 647-labeled secondary antibody (red, middle panel). Nuclei were counterstained with Hoechst 33342 fluorescent stain (blue, top panel). The two pictures were merged to show the cytoplasmic location of β-catenin staining (merge).\
**B.** Hepatic β-catenin protein level in whole cell extract was quantified using western blot analysis. The upper panel shows representative blots from western blot analysis using antibodies against β-catenin and the loading control actin. The amount β-catenin protein was normalized to actin as the relative protein abundance. The relative β-catenin protein was presented as the mean ± SEM, n= 4. Individual bars with different letters differ (P\<0.05).\
**C.** Phosphorylated β-catenin (p-β-catenin) protein level was measured using western blot and the quantifications are presented as described in Figure 3B.](nihms-444115-f0003){#F3}

![β-catenin si and NEFA treatment in H4IIEC3 cells\
H4IIEC3 hepatoma cells were cultured and treated with β-catenin si prior to the NEFA treatment.\
**A.** β-catenin protein level was measured by western blot analysis. The upper panel shows a representative western blot of β-catenin. A fast green stained non-specific band was used as the loading control. The lower panel shows the quantification of relative β-catenin protein as the mean ± SEM, n= 3. \*P\<0.05; Bracket, P\<0.05 comparing N/S si to β-catenin si in BSA treatment.\
**B.** Representative images of Oil Red O staining in N/S si (left panel) and β-catenin si (right panel) in both control (BSA, top panel) and NEFA (bottom panel) treated cells. The nucleus was stained in blue and the neutral lipid droplets were stained in red. Scale bar: 100 μm.\
**C.** Quantification of Oil Red O staining in N/S and β-catenin si is presented as the percentage of total surface area in the unit of cm^2^ using computer-assisted image quantification. The open bars represent the control N/S si group. The solid bars represent the β-catenin si group. Data are presented as the mean ± SEM, *n* = 10. \*P\<0.05; Bracket, P\<0.05 comparing N/S si to β-catenin si in BSA treatment.](nihms-444115-f0004){#F4}

###### 

Table. Gene expression in the liver of lean and obese rats^[1](#TFN1){ref-type="table-fn"},\ [2](#TFN2){ref-type="table-fn"}^

  Liver Tissue Transcript   Lean             Obese                             
  ------------------------- ---------------- ---------------- ---------------- ----------------
  ***LXRα***                8.46±0.49        8.18±1.18        10.07±0.88       9.83±0.85
  ***PPARα***               0.93±0.07        0.88±0.1         1.27±0.19        1.34±0.1
  ***SREBP1-c***            0.5±0.06^c^      0.36±0.04^c^     1.38±0.13^a^     1.09±0.06^b^
  ***ADRP***                0.38±0.04^c^     0.36±0.05^c^     1.6±0.17^a^      1.05±0.21^b^
  ***Wnt 1***               0.02±0.009       0.08±0.02        0.04±0.02        0.05±0.02
  ***Wnt 2***               0.61±0.08        0.62±0.1         0.28±0.04        0.44±0.07
  ***Wnt 2b***              0.95±0.12^a,b^   0.94±0.04^a,b^   1.11±0.12^a^     0.73±0.09^b^
  ***Wnt 3a***              0.008±0.003      0.01±0.008       0.02±0.01        0.008±0.004
  ***Wnt 4***               0.17±0.02^b^     0.17±0.03^b^     0.28±0.02^a^     0.15±0.007^b^
  ***Wnt 8b***              0.15±0.05^a^     0.38±0.12^a^     0.19±0.05^a^     0.15±0.05^a^
  ***Wnt 9a***              0.51±0.13^b^     0.30±0.22^b^     1.27±0.14^a^     0.67±0.08^b^
  ***Wnt 9b***              0.89±0.06^a^     1.13±0.10^a^     0.90±0.11^a^     0.61±0.07^b^
  ***Wnt 11***              0.16±0.05^a^     0.33±0.10^a^     0.33±0.10^a^     0.11±0.06^a^
  ***SFRP 1***              0.23±0.04^a^     0.3±0.05^a^      0.31±0.05^a^     0.18±0.04^b^
  ***SFRP 2***              0.07±0.02        0.1±0.02         0.06±0.007       0.06±0.01
  ***SFRP 4***              0.04±0.01^a,b^   0.08±0.02^b^     0.03±0.007^a^    0.007±0.001^b^
  ***SFRP 5***              0.05±0.02^a,b^   0.11±0.04^a^     0.08±0.03^a,b^   0.03±0.006^b^
  ***DKK1***                0.02±0.01^b^     0.2±0.05^a,b^    0.16±0.08^a^     0.02±0.01^b^

All mRNA analysis data are normalized as the ratio to the internal control *L7a* and expressed as means ± SEM, n=6.

Letters are assigned by post hoc comparison. Values with different letter assignment differ (p\<0.05).
